



**CRT Plenary Meeting - "THE FUTURE OF CLINICAL TRIALS:
TOWARDS DIVERSITY AND INCLUSION" –
5-6 JULY 2023 – STEIGENBERGER HOTEL HERRENHOF – VIENNA**

Faculty Biographies

- [Prof. Faiez ZANNAD, France](#)
- [Dr. Harriette VAN SPALL, Canada](#)
- [Dr. Kristine BUCHHOLTZ, NOVONORDISK](#)
- [Prof. Martin COWIE, ASTRAZENECA](#)
- [Dr. André ZIEGLER, ROCHE DIAGNOSTICS](#)
- [Prof. Salim YUSUF, Canada](#)
- [Dr. Clyde YANCY, USA](#)
- [Prof. Kamlesh KHUNTI, United Kingdom](#)
- [Dr. Eduard SHANTSILA, United Kingdom](#)
- [Mr. Richard MINDHAM, United Kingdom](#)
- [Prof. Habib GAMRA, Tunisia](#)
- [Prof. Eva PRESCOTT, Denmark](#)
- [Prof. Marion MAFHAM, United Kingdom](#)
- [Prof. Otavio BERWANGER, United Kingdom](#)
- [Prof. Eric VICAUT, France](#)
- [Dr. Lehana THABANE, Canada](#)
- [Prof. Maciej KOSTRUBIEC, Poland](#)
- [Dr. Fred SENATORE, USA](#)
- [Dr. Thomas HUCKO, AMGEN](#)
- [Prof. Angela MAAS, The Netherlands](#)
- [Dr. Michael GIBSON, USA](#)
- [Dr. Guiomar MENDIETA BADIMON, Spain](#)
- [Dr. Mohamed B JALLOH, Canada](#)
- [Prof. Cecilia LINDE, Sweden](#)
- [Dr. Stefano CORDA, BAYER](#)
- [Ms. Rebecca ORTEGA, USA](#)



Prof Faiez ZANNAD,

MD, Cardiologist, PhD in clinical pharmacology (Nancy, Lyon, and Oxford).

Emeritus Professor of Therapeutics at the Université of Lorraine, Past Director Division of Heart Failure and Hypertension, and of the Inserm Clinical Investigation Center, Nancy, France. Eugene Braunwald Scholar. (2019), European Society of Cardiology- Heart Failure Association (ESC -HFA) Lifetime Achievement Award (2017), European Society of Hypertension Paul Milliez Award (2014).

Faiez Zannad has pioneered and made significant contributions to research and care in heart failure (HF), building the evidence supporting modern HF therapy, including mineralocorticoid receptor antagonists, beta-blockers, SGLT2 inhibitors and anticoagulants, as well as in major comorbid conditions in HF, such as sleep-disordered breathing, autonomic nervous dysfunction, diabetes, hyperkalemia and chronic kidney disease. He is currently steering several major HF trials. He has also a special interest in the cardiac and kidney intersections and in the science of biomarkers. He implemented successfully the largest HF disease management program in France (ICALOR).

He has served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on Pharmacology and Drug Therapy and was a board member of the HFA of the ESC. He is the founder and chairman of the Global Cardiovascular Clinical Trialists (CVCT) Forum and Workshop, an annual international think tank meeting dedicated to the science of clinical trials, with meetings in Paris, Washington DC, Asia and the Middle East.



Dr. Harriette VAN SPALL,

Dr. Harriette Van Spall

Harriette GC Van Spall MD MPH FRCPC (Cardiology)

Associate Professor of Medicine

Director of E-Health and Virtual Care

Division of Cardiology, Department of Medicine

Department of Health Research Methods, Evidence, and Impact

Scientist, Population Health Research Institute and Research Institute of St. Joe's

McMaster University

Dr. Van Spall completed her medical and postgraduate clinical training at the University of Toronto, and earned a Master of Public Health degree at Harvard University. She is an Associate Professor of Medicine and cardiologist, and serves as Director of E-Health at McMaster University. Dr. Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on Heart Failure, health services, and health disparities. She has garnered more than \$6 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.



Dr. Kristine BUCHHOLTZ,
NOVONORDISK

Kristine Buchholtz, MD, PhD, MBA

Vice President, cardiovascular diseases

Global Medical Affairs

Novo Nordisk A/S

Kristine Buchholtz is the Vice President responsible for cardiovascular diseases in Global Medical Affairs in Novo Nordisk A/S. She has many years of both clinical and research experience within cardiology, and she is a board-certified specialist in Cardiology and Internal Medicine. Prior to joining Novo Nordisk in 2016 she worked as a cardiologist at Copenhagen University Hospital, Rigshospitalet. She holds a medical degree and a PhD from the University of Copenhagen and has an MBA from Copenhagen Business School.



**Prof. Martin COWIE,
ASTRAZENECA**

After working as a clinical academic cardiologist in the UK NHS for more than 20 years (with a particular interest in heart failure, and innovation and implementation) I was delighted to take up the role of Clinical Vice President in Late Stage (Cardiovascular, Renal & Metabolic) R & D at AstraZeneca, based out of Cambridge UK, as from August 2022. From April 2023 I became responsible for the cardiovascular (including heart failure) portfolio.

In this role, I help drive strategy across the entire value chain of the cardiovascular and heart failure portfolio, stimulating novel scientific research and innovative development designs, and lead the global clinical development strategy. This includes small molecules, antibodies and other biologics, gene silencers, and cell therapies.

Previously I was Chair of the Digital Health Committee of the European Society of Cardiology (2019-2022) and from 2016-2020 was a Non-Executive Director of the National Institute for Health and Care Excellence (NICE). I was a Consultant Cardiologist at the Royal Brompton Hospital (part of Guy's & St Thomas' NHS Foundation Trust) and led the multi-professional heart failure service there from 2001 until 2022, looking after thousands of patients with complex cardiovascular problems.

I remain as Adjunct Professor at the School of Cardiovascular Medicine (Faculty of Lifesciences and Medicine) at King's College London, Visiting Professor at Imperial College London, and Honorary Consultant Cardiologist at the Brompton Hospital, London. Please see PubMed for a list of my publications: h-index currently 91.

Highlights include establishing the evidence base for the use of blood biomarkers for the diagnosis of heart failure; randomised trials of drug therapies, devices and remote monitoring in heart failure; health technology assessments of a range of interventions; and clinical guidelines - assisting in building the evidence base to ensure patient access to novel life-changing therapies.

Working in partnership with patients has been a lifelong passion. I was previously a Trustee of the Atrial Fibrillation Association, and Chair of the Clinical Advisory Board of the patient-led heart failure charity, Pumping Marvellous. I now work to ensure our clinical trial programmes are patient- (and site-) centric.



**Dr. André ZIEGLER,
ROCHE DIAGNOSTICS**

André Ziegler (Rotkreuz, Switzerland)

André Ziegler is Global Clinical Leader for Cardiovascular Diseases at Roche Diagnostics International. He studied Pharmacy at the Universities of Basel and Geneva (Switzerland). He holds a PhD on cardiac metabolism from the Basel University. He worked as a postdoctoral researcher at the Boston University Medical School and the Institute of Molecular Biology (Biozentrum) at Basel University with various clinical methods (e.g. cardiac MRI, clinical mass spectrometry), institutes (Basel University Hospital, Institute for Pharmaceutical Sciences) and several diagnostic and pharmaceutical industries. In Roche, he is responsible for the clinical studies used for global registrations of cardiac solutions and all clinical development programs for new cardiac biomarkers (e.g. heart failure, atrial fibrillation, coronary artery disease) and instruments (e.g., cardiac point of care solutions). André is convinced that the therapeutic progress in Oncology in the last 20 years through personalized healthcare can be translated in parts also to cardiology by closer collaboration of the research partners, better therapy stratification and identification of new biotargets. Interdisciplinary collaboration for research has always been a central focus of his activities. He contributed to several FP7/Horizon 2020/Europe consortia, North American academic consortia and also initiated collaborations of Diagnostics with >10 pharmaceutical companies, and Global Clinical Chemistry associations (e.g. IFCC). Lately he has expanded his responsibilities in Roche to all clinical activities also to diagnostic solutions in Acute Care Medicine, Coagulation and Hematology. Roche Diagnostics is globally active in all market segments, from clinical research and clinical laboratory systems to patient self-monitoring. In the CRT, André is active since 2016 and had contributed to the nucleus from 2018 to 2021.




Prof Salim YUSUF,

Salim Yusuf, D.Phil, FRCPC, FRSC, O.C., is a Distinguished University Professor of Medicine at McMaster University, and Executive Director of the Population Health Research Institute. He holds a Heart and Stroke Foundation Research Chair, was a Senior Scientist of the Canadian Institutes of Health Research (1999-2004). His work has advanced the prevention and treatment of cardiovascular diseases around the world and has pioneered and demonstrated the value of dual antithrombotic therapies, ACEinhibitors and the polypill to reduce CVD substantially around the world.

He has received the Lifetime Research Achievement award of the World Heart Federation, the Paul Wood Silver Medal of the British Cardiac Society, the European Society of Cardiology gold medal, the American Heart Association Clinical Research Award, the Canada Gairdner-Wightman Prize, the McLaughlin medal of the Royal Society of Canada, the Killam Prize of the Canada Council of Arts and over 80 other international and national awards for research. He has also been inducted into the Canadian Medical Hall of Fame, and appointed as an Officer of the Order of Canada.

He has been conferred 4 honorary doctorates. He has led over 50 major international studies in over 100 countries and several of these have changed medical practice. He has published over 1200 articles in refereed journals, was the second most cited researcher in the world for 2011, the highest cited researcher in cardiology over several years and has the 17th highest H factor in history. He is a Past President of the World Heart Federation, where he initiated the Emerging Leaders program (now named after him) to build capacity for implementation and policy research in all continents of the world, with the aim of halving the CVD burden globally within a generation.



Dr. Clyde YANCY,

Clyde W. Yancy, MD, MSc,

MACC, MACP, FAHA, FHFA, FASPC (Hon.), FRCP

Clyde W. Yancy, MD, MSc is Vice Dean for Diversity, Equity and Inclusion; Magerstadt Endowed Professor & Chief of Cardiology; and Professor, Department of Medical Social Science, at Northwestern University Feinberg School of Medicine, Chicago, IL.

He serves as Associate Director, Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, IL. Dr. Yancy is Deputy Editor for JAMA - Cardiology, a former President of the American Heart Association, and holds extensive government service including leadership positions in the National Institutes of Health, the Food and Drug Administration, and the Department of Health and Human Services.

His research addresses heart failure, heart transplantation, outcomes sciences and health disparities. He has published more than 700 peer-reviewed manuscripts, and is annually cited as one of the top 1% scientific authors, worldwide. He holds innumerable awards as a healthcare leader, top physician, teacher and mentor in cardiology. He is an elected member of the National Academy of Medicine, Association of American Physicians and the Association of University Cardiologists.



Prof Kamlesh KUNTI,

Kamlesh Khunti CBE MD PhD FRCP FRCGP FMedSci

Diabetes Research Centre, University of Leicester, Leicester, UK
<https://www2.le.ac.uk/colleges/medbiopsych/research/drc/people-1/staff-pages/professorkamlesh-khunti>

Kamlesh Khunti is Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester, UK.


He has led a programme of work during the Covid-19 pandemic and is a member of UK Governments Scientific Advisory Group for Emergencies (SAGE) and Chair of the SAGE Ethnicity Sub-panel. Professor Khunti is also Director of the UK National Institute for Health Research (NIHR) in Applied Research Collaborations (ARC) East Midlands, Director of Centre for Ethnic Health Research and Director of The Real World Evidence Unit. He has published over 1000 peer-reviewed articles. He is also Honorary Visiting Professorial Fellow with Department of General Practice, University of Melbourne. He is named as Top T2 diabetes researcher globally by Expertscape. He has won numerous awards nationally and internationally and was awarded the CBE in the 2022 New Year's Honour's List for services to health.

@kamleshkhunti



Dr. Eduard SHANTSILA

Eduard Shantsila is a general practitioner with previous long-standing experience as a cardiologist. As a researcher, he is a Senior Clinical Lecturer in Primary Care at the University of Liverpool with expertise in cardiovascular research. This allows me to see the perspectives of both primary and secondary care colleagues and facilitate mutually beneficial collaborations. His clinical and research interests lie around improving the cardiovascular health of people with health inequalities in hard-to-reach populations underrepresented in clinical trials. The patient group include people from ethnic minority backgrounds with mental health issues, multi-morbidity, frailty and lower socioeconomic status.



Mr. Richard MINDHAM,

Richard Mindham - Patient

Career

Computing & Software, Telecoms

Dilated Cardiomyopathy 2007

Guidelines

NICE CHF 2010 & 2018

ICHOM HF Reference Guide 2016

ESC HF 2021

ESC HF 2021 – Patient Version

ESC HF Quality Indicators, 2022

NICE CHF Quality Standard, 2015 & 2022

NICE AHF Quality Standard, 2015

Association of Cardiovascular Nursing & Allied Professionals (ACNAP) Core Curriculum, 2023

Research

Royal Brompton Hospital, Patient Advisory Group, London, 2011 - present

Queens University, Belfast, Cardiac Research Group, 2021 - present

SERCA-LVAD, Steering Committee, Lay Member, 2015

IRONMAN Steering Committee, Lay Member, 2016-2022

TRED-HF Outcome Analysis, co-author, 2021

MitoDCM Trial Steering Committee, Lay Member, 2021

James Lind Alliance (Oxford University) - Priority Setting Partnership - HF Research, 2019

Reducing Bureaucracy in Clinical Trials., 2021

More-EUROPA (Horizon), Advisory Board, Lay Member, 2023

Current

ESC Patient Forum

ESC Clinical Guideline Group



Prof. Habib GAMRA,

Professor Habib Gamra obtained his medical degree from Sousse University School of Medicine (Tunisia) in 1987 before starting a residency in Cardiology at Charles Nicolle Hospital, Rouen (France) and a fellowship in interventional cardiology at the Good Samaritan Hospital and University of Southern California, Los Angeles, USA that he completed in 1993. He is currently professor in cardiology at the university of Monastir (Tunisia) since 1996 and he currently holds the following positions:

- Head of Cardiology A Department at Fattouma Bourguiba University Hospital - Monastir, Tunisia
- Chairman of the Pan African Course on Interventional Cardiology (PAFCIC) that is held annually since 2000 (www.pafcic.org)
- President of the Tunisian Heart Foundation
- Vice President North of The Panafrican Society of Cardiology (PASCAR)
- Director of Africa PCR
- Co-Director of CSI Africa congress
- Co-Chairman of Cardio Vascular Clinical Trialists MEMA meeting
- Co-Editor European Heart Journal for North Africa
- Past President of the working group on interventional cardiology of the Tunisian Society of Cardiology and Cardiovascular Surgery (GTCl)
- Past President of the African Heart Network
- Co-Chair of The Panafrican Society of Cardiology (PASCAR) Interventional Cardiology Task Force (PAsCI)
- Stent Save A Life country champion for Tunisia
- President of the regulatory specialised commission at the Tunisian Ministry of Health.

He is also in the editorial board of various national and international journals.



Prof. Eva PRESCOTT,

Professor Prescott heads the Centre for Cardiovascular Research at Bispebjerg Frederiksberg University Hospital, Copenhagen. Her main research areas are in angina pectoris, cardiac rehabilitation and epidemiological studies of precursors of CVD, including gender differences and psychosocial factors and she has published more than 350 papers. Professor Prescott has initiated and participated in several national and international randomized trials mainly in stable coronary artery disease and rehabilitation. She is also the PI of the largest prospective multicenter study of women with angina and no obstructive epicardial disease focusing on the role of microvascular dysfunction. Professor Prescott has served the congress program committee and several ESC guidelines, has chaired the ESC working group on prevention, epidemiology and population science and is currently chair of the Clinical Practice Guidelines of the ESC.



Prof. Marion MAFHAM,

Marion Mafham is an Associate Professor working in the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at Oxford Population Health. Her work aims to improve health by generating reliable randomised evidence about the effects of interventions to treat and prevent common causes of death and disability, focusing on diabetes, cardiovascular and kidney diseases. She pioneers new trial methods to design large-scale streamlined randomised trials that produce reliable answers, including the use of healthcare systems data in clinical trials and direct-to-participant designs. She is module lead for the University of Oxford's MSc in clinical trials and co-leads the clinical trials program for Health Data Research UK.

Her recent clinical trials work includes the mail-based ASCEND study in 15,480 participants with diabetes, the ongoing 15,000 participant ORION-4 study in cardiovascular disease and she co-leads the ASCEND PLUS trial of oral semaglutide in type 2 diabetes. She leads the data linkage team for the RECOVERY trial assessing potential hospital treatments for COVID-19. Her research also uses healthcare systems data to generate real time insights into the impact of COVID-19 on NHS care pathways.

She studied medicine at the University of Edinburgh (1992-1998) and completed an MD thesis at the CTSU (2003-2006). She also works as an Honorary Consultant Nephrologist at Oxford University Hospitals NHS Foundation Trust.



Prof. Otavio BERWANGER,

Professor Berwanger (MD; PhD) is a cardiologist and clinical trialist who has been serving as Chair of the Steering Committee of large-scale randomised cardiovascular clinical trials. He is currently the Executive Director of the George Institute for Global Health UK and Chair in Clinical Trials at the Imperial College London.

Professor Berwanger coordinates a network of several Research Sites in various countries and has published manuscripts in major medical journals such as New England Journal of Medicine, Lancet, and JAMA. His current research focus include the conduct of innovative decentralised clinical trial models, the use of routinely collected data in pragmatic clinical trials, as well as efficient implementation science studies.

<https://www.georgeinstitute.org.uk/people/otavio-berwanger>



Prof. Eric VICAUT,

Prof. Eric VICAUT

Assistance Publique Hôpitaux de Paris-Université Paris-Cité

Fonction : Coordonnateur – Méthodologiste de l'Unité de Recherche Clinique Lariboisière-Saint-Louis et du Centre d'Evaluation des Dispositifs Médicaux APHP (CEDM)

After a Medical Thesis and a PhD in Biostatistics and Applied Mathematics Eric Vicaut has been recruited as research fellow in INSERM. He became Research Director in INSERM in 1992 and Professor of Biophysics at the Medical University Paris –Cité in 1997.

He is the head of the Clinical Research Unit (Lariboisière St-Louis) and the Center for Medical Devices Evaluation and was co-Head of the National Platform for Clinical Research FCRIN-PARTNERS APHP.

As methodologist and biostatistician, he is involved in a large number of multicentric and international clinical trials. He published more than six hundred seventy articles in peer review journals.

For several years, he has been the methodological expert for the French Market Approval Committee for Drugs in the French regulatory agency (ANSM), and for the French Committee for Medical Devices in the French “Haute Autorité de Santé”.

He has been president of the working group “MEDICAL DEVICES” for the “Assises du Médicament” and the author of the ministerial report “Dispositifs Médicaux pour une évaluation à la hauteur des enjeux”

Since 2019 - vice-president of the MedTech sector Medicen, the Paris-Ile de France Biomedical Cluster

Since 2021- president of the Strategic and Scientific Board of the Carnot@AP-HP Institute.

Since 2022 - assistant vice-president for research of Assistance Publique Hôpitaux de Paris APHP.

☎: + 33 (01 40 05 43 66)

@ : eric.vicaut@aphp.f



Dr. Lehana THABANE,

Dr. Lehana Thabane is a Vice-President of Research at St Joseph's Healthcare—Hamilton; Scientific Director of the Research Institute at St Joseph's Healthcare; Professor of Biostatistics and Former Associate Chair of the Department of Health Research Methods, Evidence, and Impact; Associate Member of the Departments of Pediatrics, Medicine, Family Medicine, Surgery, Psychiatry and Behavioral Neurosciences, and Anesthesia, School of Nursing, and School of Rehabilitation Science, in the Faculty of Health Sciences at McMaster University. He is an Elected Member of the International Statistical Institute, Fellow of the American Statistical Association, Fellow of the Society for Clinical Trials, Fellow of the Canadian Academy of Health Sciences, and Honorary Foreign Associate Member of the Academy of Science of South Africa. He is the Past President for Society for Clinical Trials; and the Editor-in-Chief of the journal Pilot and Feasibility Studies.



Prof. Maciej KOSTRUBIEC,

Prof. Maciej Kostrubiec, MD, PhD is a professor at The Medical University of Warsaw, Fellow of the European Cardiac Society (FESC), Fellow of the European Association of Cardiovascular Imaging (FEACVI) and HFA/ESC-certified specialist in heart failure. Since 2019 he has held the position of cardiologist consultant at Mid Essex Hospital NHS Trust in the United Kingdom. Dr Kostrubiec is also a subject matter expert at The Office for Registration of Medicinal Products in Poland and The European Medicines Agency (EMA). He is a member of the EMA Cardiovascular Working Party of CHMP and an expert in the fields of cardiovascular imaging (echocardiography and cardiac CT) and invasive cardiovascular investigation. In 2021 he was granted the title of Professor by the President of the Republic of Poland in recognition of his scientific and educational achievements.

Prof. Maciej Kostrubiec obtained his MD degree at the Warsaw Medical University in Poland in 2000. Afterwards, he completed his PhD research in pulmonary embolism at the Warsaw Medical University and did his residency in Internal Medicine at the Department of Internal Medicine, Hypertension and Angiology at the Warsaw Public Central Teaching Hospital. Subsequently, he continued his clinical training and was granted the title of specialist in cardiology at the Department of Internal Medicine and Cardiology with the Centre of Diagnosis and Treatment of Venous Thromboembolic Disease, the Infant Jesus Teaching Hospital in Warsaw. At the same place, he was responsible for the development of the Pulmonary Embolism Management Program which integrated in-patient and outpatient services for patients with thromboembolic disease. Further improvement was the pharmacological and invasive (balloon pulmonary angioplasty) treatment programme for patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Prof. Kostrubiec is an internationally recognised specialist in right heart failure and pulmonary hypertension, especially secondary to venous thromboembolic disease. His scientific activities were recognised with several awards including the Presidents of the Polish Cardiac Society, the Ministry of Health, and the Rector of the Warsaw Medical University. Currently, in the UK he is primarily involved in specialist service for patients with heart failure with a special interest in HFpHF.



Dr. Fred SENATORE,

Fortunato Fred Senatore MD, PhD, FACC

Medical Officer / Team Leader

Division of Cardiology and Nephrology

Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN)

U.S. Food and Drug Administration

Dr Fred Senatore has been a medical officer in the Division of Cardiology and Nephrology at the US Food and Drug Administration since 2012 and has served as Lead Physician since January 2020. Prior to his tenure at the FDA, Dr Senatore served in the pharmaceutical industry with increasing responsibility over a span of 17 years.

Dr Senatore received his BA in Biochemistry and MS in Bioengineering from Columbia University, his PhD in Chemical Engineering from Rutgers University, his MD degree from the Texas Tech University Health Sciences Center School of Medicine, his Internal Medicine training at the Mayo Clinic, and his Cardiology training at Harvard Medical School / Massachusetts General Hospital. He was a professor of Chemical Engineering at Texas Tech University, where he was awarded grants and authored papers in areas of artificial organ technology, biocompatibility, hemodynamics, and modeling/simulation of biological processes.

While at the FDA, Dr. Senatore has published in the areas of shock, medication adherence/representative populations, benefit/risk assessment, heart failure and clinical trials during the COVID-19 pandemic. He is co-editing a textbook on Basic and Clinical Research, to be published by SPRINGER in the summer-fall 2023. Dr. Senatore is on the faculty at the FDA, teaching a variety of courses on trial design and data analysis. He also provides service to the Heart Failure Collaboratory, National Forum for Heart Disease and Stroke Prevention, Cardiovascular Clinical Trialist (CVCT) Forum, TOPRA (The Organization of Professionals in Regulatory Affairs), ACDRS (American Course on Drug Development and Regulatory Science), ECPM (European Center of Pharmaceutical Medicine), and CCDRS (Chinese Course on Drug Development and Regulatory Science).



**Dr. Thomas HUCKO,
AMGEN**

Thomas Hucko, MD is a Clinical Research Medical Director in Global Development at Amgen. He has worked on a variety of development programs across Amgen's cardiovascular-metabolic portfolio from Ph1 to Ph4, including leadership positions in large-scale cardiovascular outcomes trials and in-vitro diagnostics development; his main areas of focus are lipid disorders and heart failure. In addition, he has been responsible for clinical trials employing advanced imaging techniques. Currently, Thomas serves as global development lead and helps coordinate multi-omics strategy within his therapeutic area. Thomas obtained his medical degree at Charité Berlin, Germany and received his clinical training at the German Heart Institute Berlin where he also specialized in cardiac MRI and at the Jewish Hospital Berlin where he still works as a part-time clinician in the cardiac electrophysiology department.



Prof. Angela MAAS,

Angela Maas, MD, PhD FESC is a clinical cardiologist since more than 30 years and has developed a main interest in heart disease in women over the past decades. She established the first outpatient clinic for women in the Netherlands in 2003 and was appointed as a professor in Cardiology for women at the Radboud University, Nijmegen in 2012. Her main interests are the early identification of women at increased CV risk and symptom evaluation in women at middle-age. She has received many awards such as by the Dutch Society of female physicians (2010), the Radboud University (2014) and was knighted by the King in 2017. She has been one of the most influential female doctors in Dutch healthcare and was the 2020/21 Women's representative of the Dutch Government to the United Nations. From May 2022 onwards she focusses on research and advisory tasks only.



Dr. Michael GIBSON,


C. Michael Gibson M.S., M.D., pioneered our understanding of the open artery and the open microvasculature hypothesis in the setting of heart attack. As an innovator, Gibson invented measures of coronary blood flow that are widely used today (the TIMI frame count (cited 2,131 times), the TIMI myocardial perfusion grade (cited 1,089 times)).

Gibson is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. Gibson founded PERFUSE in 1987 which served as the TIMI Data coordinating center that coordinated data for the first 50 TIMI trials. The Baim institute was formerly known as Harvard Clinical Research Institute and was founded in 2000. The combined institutes have led over 1,000 studies, published 5,500 manuscripts in peer review literature (including 144 in the New England Journal) and have led 70 FDA submissions from their network of 7,000 sites in 57 countries worldwide. Since 2014, Gibson has consistently been ranked as one of the world's most highly cited authors in all of science by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 155,000 times, and he has an H index of 137 and an i10-index of 570.

Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 30,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack.

Gibson is currently leading the first large “Virtual” randomized trial which uses apps and the internet to eliminate “bricks and mortar” and is being conducted at 1% of the usual cost. The HEARTLINE trial of the Apple watch randomized 32,000 patients and is one of the largest randomized patient trials in cardiology history. Gibson and his team will be operationalizing many of the trial efforts evaluating Milvexian, a Factor Xi inhibitor across a variety of disease states (50,000 patients with ACS, AF, or Stroke). Gibson also is leading the AEGIS 2 trial evaluating the effectiveness of an Apo A1 infusion (the building block of good cholesterol or HDL) in 18,200 patients following an MI.

Dr. Gibson is a practicing interventional cardiologist who has held numerous leadership positions in medicine including positions as a Coronary Care Unit Director, a Cardiac Catheterization Laboratory Director, a Chief of Cardiology at Harvard Medical School affiliated hospitals and as a Vice Chairman of Medicine at a hospital of over 1,000 physicians. For years, Gibson has been chosen as one of Boston's Top Doctors & U.S. News & World Report also lists Gibson as one of America's top doctors. Dr. Gibson obtained his BS, MS, and MD degrees at the University of Chicago where he was a Phi Beta Kappa and AOA graduate and was a starting half back. He then went on to do his internship, residency and chief residency at the Brigham and Women's Hospital and his cardiology fellowship at the Beth Israel Deaconess Medical Center both at Harvard Medical School.



Dr. Guiomar MENDIETA BADIMON,

GUIOMAR MENDIETA MD, PhD, MSc

Guiomar Mendieta MD PhD MSc is currently a Cardiovascular Imaging Fellow at Hospital Clinic in Barcelona, and a Clinical Research Fellow at IDIBAPS, Barcelona and at the National Center of Cardiovascular Investigation (CNIC) in Madrid, Spain. She received her MD at Universitat Autònoma de Barcelona, Spain (2014) and performed her Cardiology residency training at Hospital Clínic de Barcelona, Spain (2015-2020). Dr. Guiomar Mendieta performed translational research studies in cardioprotection, obtaining her Philosophy Degree in Medicine in 2020. She was then awarded a 3-year competitive CardioJoven fellowship offered by the Spanish Society of Cardiology/CNIC. During the last 2 years, she has performed a MSc in Epidemiology at the London School of Hygiene and Tropical Medicine, London, UK (2021), and attended the Post-Graduate Course in Heart Failure at the European Heart Academy of ESC-Heart Failure Association in the University of Zurich, Zurich, Switzerland (2022). She has published 40 scientific articles. She is a past Cardiovascular Clinical Trials (CVCT) Future Trialist Fellow and is currently the CVCT Future Trialist program coordinator.



Dr. Mohamed B JALLOH,

Dr. Mohamed Bella Jalloh is a research fellow at McMaster University working under the supervision of Dr. Harriette Van Spall. His main interests lie in clinical trial methodology and implementation science, along with the development of novel therapeutic options for cardiovascular diseases. He is actively involved in a multi-centre randomized controlled trial in heart failure.

Bella earned his medical degree from the University of Sierra Leone and a Master of Science from the University of Oxford. He has a distinguished background as a global health scholar at Oxford, supporting global health initiatives.



Prof. Cecilia LINDE,

Cecilia Linde is a Professor in Cardiology at Karolinska University Hospital and the Karolinska Institutet in Stockholm, Sweden. Her research focuses on devices such as cardiac resynchronization therapy (CRT) and cardiac contractility modulation (CCM) and epidemiology in heart failure. She was the principal or co-principal investigator of international RCTs on CRT or CCM such as the MUSTIC, REVERSE, MIRACLE-EF and the CCM HFpEF studies. She chairs the Stockholm PREFERS studies and co-chaired the KaRen study which focus on epidemiology, imaging and biomarkers in heart failure with special attention to HFpEF. She has served in various board leadership positions of ESC. 2016-2018 as councillor, 2018–2020 as Vice President and currently as Secretary Treasurer of the European Society of Cardiology (ESC) 2022-2024. Board Professor Linde contributed to many guideline writing committees of European Heart Rhythm Association and Heart Failure Association. She has authored over 300 papers, reviews and editorials covering a wide variety of topics and since 2020 is the executive editor for the topic heart failure of European Heart Journal.



Dr. Stefano CORDA,

BAYER

After completing Medical training in Italy I obtained a visiting fellowship at the Laboratory of cardiovascular Science at NIH in Baltimore (USA) where I spent 3 years (1992-95) working on models of endothelial and cardiac cell signaling. I subsequently obtained a postdoctoral fellowship of the EU program Pierre and Marie Curie and joined in parallel a PhD program in Cardiovascular physiology at Universite' Paris 7 in Paris, which I completed in 1998. Was appointed as an Assistant Professor at the same University, School of Medicine, Dept of Biophysics (1998-2000).

I joined the Pharmaceutical industry in 2000, and held roles of increasing responsibility in Translational Science, Early clinical development (Vascular Medicine and Thrombosis) and Medical affairs in Servier, where I served as a Medical Affairs Director for the clinical studies in Hypertension ADVANCE and HYVET, Novartis (Clinical development and Medical Affairs in Heart Failure and Atherosclerosis), with leading positions in Medical Affairs on the studies PARADIGM-HF, PARAGON-HF and CANTOS) and, since 2020, Bayer (Cardiorenal Department), with a Clinical Lead role in the vericiguat program in HF (VICTORIA and VICTOR studies, the latter ongoing).



Ms. Rebecca ORTEGA,

Rebecca Ortega, MHA is the Executive Director of Women as One, a nonprofit organization aimed at promoting talent in medicine by providing unique professional opportunities to women physicians. As the organization's Executive Director, she drives strategic development, operations management and fundraising with a particular interest in innovative medical education and implementation initiatives. Rebecca was previously the Director of Strategic Development at the Icahn School of Medicine at Mount Sinai where she led business development activities for the Center for Interventional Cardiovascular Research and Clinical Trials, including the launch of the Lancet Women and Cardiovascular Disease Commission to reduce the global burden of disease in women worldwide. Prior, she was the Director of Education at the Duke Clinical Research Institute in Durham, NC and before that, the Director of Education at the Society for Cardiovascular Angiography and Interventions in Washington, DC where her focus was on building and funding de novo educational programs and assuring regulatory compliance. She holds a master's degree in health systems administration from Georgetown University and a Bachelor of Arts degree from Davidson College.